MRKMerck Sharp & Dohme LLCRunning, no new patients
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
Melanoma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 976 (final count)
- Started
- Sep 12, 2018
- Main results expected
- Jun 21, 2021
- Fully finished
- Oct 12, 2033
- Results posted
- Jun 24, 2022
What counts as success
The trial's main goal(s), called the “primary outcome.”
Recurrence-free Survival (RFS)
Measured over: Up to ~32.7 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03553836 · record last updated 2024-11-29 · checked 2026-11-09 15:47 UTC